ZA200608712B - Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor - Google Patents
Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor Download PDFInfo
- Publication number
- ZA200608712B ZA200608712B ZA200608712A ZA200608712A ZA200608712B ZA 200608712 B ZA200608712 B ZA 200608712B ZA 200608712 A ZA200608712 A ZA 200608712A ZA 200608712 A ZA200608712 A ZA 200608712A ZA 200608712 B ZA200608712 B ZA 200608712B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- inhibitors
- ikk
- inflammatory
- amino
- Prior art date
Links
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title description 5
- 229940043355 kinase inhibitor Drugs 0.000 title description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 134
- 150000003839 salts Chemical class 0.000 claims description 43
- 239000003112 inhibitor Substances 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 16
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 230000005713 exacerbation Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000000414 obstructive effect Effects 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 5
- 238000011861 anti-inflammatory therapy Methods 0.000 claims description 5
- 229940124630 bronchodilator Drugs 0.000 claims description 5
- 239000000812 cholinergic antagonist Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229960002848 formoterol Drugs 0.000 claims description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001361 ipratropium bromide Drugs 0.000 claims description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 3
- 230000003843 mucus production Effects 0.000 claims description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- 229960000257 tiotropium bromide Drugs 0.000 claims description 3
- 238000012387 aerosolization Methods 0.000 claims description 2
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims 4
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 4
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 29
- 102000003945 NF-kappa B Human genes 0.000 description 27
- 108010057466 NF-kappa B Proteins 0.000 description 27
- 230000004913 activation Effects 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 210000004072 lung Anatomy 0.000 description 21
- 108091000080 Phosphotransferase Proteins 0.000 description 20
- 239000002253 acid Substances 0.000 description 20
- 102000020233 phosphotransferase Human genes 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- -1 {(cyano (ethoxycarbonyl)methylene)-amino)-N, N, N’, N’-tetramethyluronium tetrafluoroborate Chemical compound 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000004400 serine Nutrition 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- OVRSIQWVIJSERH-UHFFFAOYSA-N 1-(dimethylamino)-4,4-dimethoxypent-1-en-3-one Chemical compound COC(C)(OC)C(=O)C=CN(C)C OVRSIQWVIJSERH-UHFFFAOYSA-N 0.000 description 5
- VGPFMJFWIPSHJO-UHFFFAOYSA-N 2-[2-(methylamino)pyrimidin-4-yl]-1h-indole-5-carboxylic acid Chemical compound CNC1=NC=CC(C=2NC3=CC=C(C=C3C=2)C(O)=O)=N1 VGPFMJFWIPSHJO-UHFFFAOYSA-N 0.000 description 5
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 5
- 102100039065 Interleukin-1 beta Human genes 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 150000002475 indoles Chemical class 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014561 Emphysema Diseases 0.000 description 3
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101150091206 Nfkbia gene Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 150000001556 benzimidazoles Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ICBAJJBPHLBVEN-UHFFFAOYSA-N 2-[[2-[2-(methylamino)pyrimidin-4-yl]-1h-indole-5-carbonyl]amino]-3-(n-pyridin-2-ylanilino)propanoic acid Chemical compound CNC1=NC=CC(C=2NC3=CC=C(C=C3C=2)C(=O)NC(CN(C=2C=CC=CC=2)C=2N=CC=CC=2)C(O)=O)=N1 ICBAJJBPHLBVEN-UHFFFAOYSA-N 0.000 description 2
- UFQBSPGKRRSATO-UHFFFAOYSA-N 3,3-dimethoxybutan-2-one Chemical compound COC(C)(OC)C(C)=O UFQBSPGKRRSATO-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 239000003458 I kappa b kinase inhibitor Substances 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 2
- 101710164423 Mitogen-activated protein kinase kinase kinase 1 Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 101100482130 Xenopus laevis fbxw1 gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 108010073357 cyanoginosin LR Proteins 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- ZYZCGGRZINLQBL-GWRQVWKTSA-N microcystin-LR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-GWRQVWKTSA-N 0.000 description 2
- DIDLWIPCWUSYPF-UHFFFAOYSA-N microcystin-LR Natural products COC(Cc1ccccc1)C(C)C=C(/C)C=CC2NC(=O)C(NC(CCCNC(=N)N)C(=O)O)NC(=O)C(C)C(NC(=O)C(NC(CC(C)C)C(=O)O)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(NC(=O)C2C)C(=O)O)C(=O)O DIDLWIPCWUSYPF-UHFFFAOYSA-N 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- AWNBSWDIOCXWJW-WTOYTKOKSA-N (2r)-n-[(2s)-1-[[(2s)-1-(2-aminoethylamino)-1-oxopropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n'-hydroxy-2-(2-methylpropyl)butanediamide Chemical compound C1=CC=CC2=CC(C[C@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(=O)N[C@@H](C)C(=O)NCCN)=CC=C21 AWNBSWDIOCXWJW-WTOYTKOKSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VJQCNCOGZPSOQZ-UHFFFAOYSA-N 1-Methylguanidine hydrochloride Chemical compound [Cl-].C[NH2+]C(N)=N VJQCNCOGZPSOQZ-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UHTQHHLSGVOGQR-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate Chemical compound OCCN1CCN(CCS(O)(=O)=O)CC1.OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 UHTQHHLSGVOGQR-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001043754 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940122296 IKK2 inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102000011202 Member 2 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101710161549 NADPH quinone oxidoreductase Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000192497 Oscillatoria Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical compound N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940049268 euthasol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940083668 ketek Drugs 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- HUDSSSKDWYXKGP-UHFFFAOYSA-N n-phenylpyridin-2-amine Chemical compound C=1C=CC=NC=1NC1=CC=CC=C1 HUDSSSKDWYXKGP-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
SUBSTANTIALLY PURE 2-{[2-(2-METHYLAMINO-PYRIMIDIN-4-YL)-1H- INDOLE-5-CARBONYL]-AMINO}-3-(PHENYLPYRIDIN-2-YL-AMINO)-PROPIONIC ACID
AS AN IxB KINASE INHIBITOR
This invention is directed to an indole derivative, its preparation, a pharmaceutical composition comprising the compound, its use, and intermediates thereof.
NF-kB is a heterodimeric transcription factor that regulates the expression of multiple inflammatory genes. The expression of more than 70 known proteins is transcriptionally regulated by the binding of
NF-kB to specific sequence elements in the promoter region of these genes (Baeuerle and Baichwal,
Advances in Immunology 65:111-137, 1997). NF-kB has been implicated in many pathophysiologic processes including angiogenesis (Koch et al., Nature 376:517-519, 1995), atherosclerosis (Brand et al., J Clin Inv. 97: 1715-1722, 1996), endotoxic shock and sepsis (Bohrer et al., J. Clin. Inv. 100:972- . 085, 1997), inflammatory bowel disease (Panes et al., Am J Physiol. 269:H1955-H1964, 1995), ischemia/reperfusion injury (Zwacka et al., Nature Medicine 4:698-704, 1998), and allergic lung inflammation (Gosset et al., Int Arch Allergy Immunol. 106:69-77, 1995). Thus the inhibition of NF-
KB by targeting regulatory proteins in the NF-xB activation pathway represents an attractive strategy for generating anti-inflammatory therapeutics due to NF-xB’s central role in inflammatory conditions.
The IkB kinases (IKKs) are key regulatory signaling molecules that coordinate the activation of NF- kB. Two IKKs, IKK-1 (IKK-0) and IKK-2 (IKK-P), are structurally unique kinases containing an N- terminal kinase domain with a dual serine activation loop, a leucine zipper domain, and a C-terminal helix-loop-helix domain and serine cluster. IKK enzymes show relatively low sequence homologies with other kinases, and early profiles with known kinase inhibitors have not identified compounds with striking potency. Kinetic analysis shows that IKK-2 binds to and phosphorylates IkBa, and IxBe with high and relatively equal affinities (Heilker et al. 1999). Recombinant IKK-2 phosphorylates kB
4 | a peptide 26-42 with near equal affinity to full length IxBo, however the native IKK enzyme complex phosphorylates full length IxBat 25,000 fold more efficiently, suggesting important regulatory sequences in the C-terminal region of IkBa, or additional regulatory proteins in the IKK enzyme complex that accelerate the rate of catalysis (Burke et al., Journal of Biological Chemistry 274:36146- 36152, 1999). Phosphorylation of IkBa occurs via 2 random sequential kinetic mechanism, meaning either ATP or IkBat may bind first to IKK-2, that both must be bound before phosphorylation of IxBa can take place (Peet and Li, Journal of Biological Chemistry 274:32655-32661, 1999). IKK-2 binds
ATP with uniquely high affinity (Ki=130 nM) compared to other serine-threonine kinases such as p38 and JNK perhaps indicating a unique ATP binding pocket that reflects the relatively poor activity to many broad specificity kinase inhibitors when tested against IKK-2. To date, no crystal structure of
IKK-2 has been reported. However homology modeling has identified 3 structural domains including an N-terminal kinase domain with an activation loop, a leucine zipper domain that likely mediates the formation of IKK-1 and IKK-2 homo/heterodimers, and a C-terminal helix-loop-helix with serine rich tail. Activation of IKK-2 is dependent upon phosphorylation of serine 177 and 181 in the activation or T loop. Alanine mutations abolish activity, while glutamate mutations result in a constitutively active enzyme (Mercurio et al. Science 278:860-866, 1997; Delhase et al., Science 284:30 313, 1999).
IKK-1 and IKK-2 occur both as heterodimers and IKK-2 homodimers, and are associated with a 700- 900 kDa cytoplasmic enzyme complex called the "IKK Signalsome” (Mercurio et al, Science 278:860-866, 1997). Another component, IKKAP-1 or NEMO/IKKy has no apparent catalytic function but will associate directly with IKK-2 and is necessary for full activation of NF-kB (Mercurio et al., Mol Cell Biol 19:1526-1538, 1999). Many immune and inflammatory mediators including
TNFa, lipopolysaccharide (LPS), IL-18, CD3/CD28 (antigen presentation), CD40L, FasL, viral infection, and oxidative stress have been shown to lead to NF-kB activation. Although the receptor complexes that transduce these diverse stimuli appear very different in their protein components, it is understood that each of these stimulation events leads to activation of the IKKs and NF-kB.
The IKK complex appears to be the central integrator of diverse inflammatory signals leading to the phosphorylation of IxB. IKKs are activated at dual serine residues by upstream kinases including NF- xB inducing kinase, NIK (Malinin et al., Nature 385:540-544, 1997), and MEKK-1 (Yujiri et al.,
Science 282:1911-1914, 1998). The differential activities of NIK and MEKK-1 remain unclear although initial data indicates these kinases may preferentially activate IKK-1 and IKK-2, respectively.
Activated IKK phosphorylates a cytoplasmic inhibitor protein, IxB that binds NF-kB, thereby masking a nuclear localization signal present in Rel proteins (Cramer et al., Structure 7: R1-R6, 1999). IKK phosphorylation of IxB on serines 32 and 36 forms a structural motif recognized by the E3 ligase,
BTRcP (Yaron et al., Nature 396:590-594, 1998). Docking of BTRcP results in the formation of a ligase complex which polyubiquitinates IKB thus targeting it for degradation by the 26S proteosome.
Free NE-xB is then identified by nuclear transport proteins, which translocate it to the nucleus where it can associate with sequence specific regulatory elements on gene promoters.
Although both kinases can phosphorylate IkB in vitro, early studies using genetic mutants indicated that IKX-2, but not IKX-1, was essential for activation of NF-kB by pro-inflammatory stimuli such as
IL-1 and TNFa. Furthermore, only catalytically inactive mutants of IKK-2 blocked the expression of
NF-kB regulated genes such as monocyte chemotactic protein (MCP-1) and intercellular adhesion molecule (ICAM-1) (Mercurio et al, Science 278:860-866, 1997). Studies of knockout animals for
IKK-1 and IKK-2 substantiate these initial findings (Hu et al., Science 284:316-320, 1999; Liet al,
Genes & Development 13:1322-1328, 1999; Li et al., Science 284:321-324, 1999; Takeda et al.,
Science 84:313-316, 1999; Tanaka et al., Immunity 10:421-429, 1999). IKK-1" animals were born alive but died within hours. Pups showed abnormalities of the skin due to defective proliferation and differentiation, but showed no gross deficiency in cytokine induced activation of NF-xB. In contrast,
IKK-2" embryos died at day 14-16 of pregnancy from liver degeneration and apoptosis that bore a . striking resemblance to that observed in Rel A knock-out animals (Beg et al., Nature 376: 167-170, 1995). Furthermore, embryonic fibroblasts from IKK-2" animals exhibited markedly reduced NF-xB activation following cytokine stimulation, while IKK-1" did not.
Accordingly, cell and animal experiments indicate that IKK-2 is a central regulator of the pro- : inflammatory role of NF-xB, wherein the IKK-2 is activated in response to immune and inflammatory stimuli and signaling pathways. Many of those immune and inflammatory mediators, including IL-18,
LPS, TNFa, CD3/CD28 (antigen presentation), CD40L, FasL, viral infection, and oxidative stress, play an important role in respiratory diseases. Furthermore, the ubiquitous expression of NF-kB, along with its response to multiple stimuli means that almost all cell types present in the lung are potential target for anti-NF-xB/IKK-2 therapy. This includes alveolar epithelium, mast cells, fibroblasts, vascular endothelium, and infiltrating leukocytes, including neutrophils, macrophages, lympophocytes, eosinophils and basophils. By inhibiting the expression of genes such as cyclooxygenase-2 and 12- lipoxygenase (synthesis of inflammatory mediators), TAP-1 peptide transporter (antigen processing),
MHC class I H-2K and class II invariant chains (antigen presentation), E-selectin and vascular cell adhesion molecule (leukocyte recruitment), interleukins-1, 2, 6, 8 (cytokines), RANTES, eotaxin, GM-
CSF (chemokines), and superoxide dismutase and NADPH quinone oxidoreductase (reactive oxygen species), inhibitors of IKK-2 are believed to display broad anti-inflammatory activity.
Patent application WO 94/12478, the content of which is incorporated herein by reference, describes, inter alia, indole derivatives that inhibit blood platelet aggregation. Patent applications WO 01/00610 and WO 01/30774, the content of each of which is incorporated herein by reference, describe indole derivatives and benzimidazole derivatives, which are able to modulate NF-xB. As described above,
S NF-kB is a heterodimeric transcription factor that is able to activate a large number of genes that encode, inter alia, proinflammatory cytokines such as IL-1, IL-2, TNFa or IL-6. NF-xB is present in the cytosol of cells, where it is complexed with its naturally occurring inhibitor IxB. Stimulation of the cells, for example by cytokines, leads to the IxB being phosphorylated and subsequently broken down proteolytically. This proteolytic breakdown leads to the activation of NF-kB, which then migrates into the nucleus of the cell, where it activates a large number of proinflammatory genes.
In diseases such as rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disorder (COPD), rhinitis, multiple sclerosis, cardiac infarction, Alzheimer’s diseases, diabetes Type II, inflammatory bowel disease or atherosclerosis, NF-kB is activated beyond its normal extent. The inhibition of NF-kB is also described as being useful for treating cancer on its own or in addition to cytostatic therapy. Inhibition of the NF-xB-activating signal chain at various points or by interfering directly with the transcription of the gene by glucocorticoids, salicylates or gold salts, has been shown as being useful for treating rheumatism.
The first step in the abovementioned signal cascade is the breakdown of IxB. This phosphorylation is regulated by the specific IB kinase. Thus far, inhibitors of IxB kinase are known to frequently suffer from the disadvantage of being non-specific for inhibiting only one class of kinases. For example, most inhibitors of IxB kinase inhibit several different kinases at the same time because the structures of the catalytic domains of these kinases are similar. Consequently, the inhibitors act, in an undesirable manner on many enzymes, including those that possess the vital function.
Chronic obstructive pulmonary disease (COPD) is a debilitating inflammatory disease of the lungs characterized by the progressive development of airflow limitation that is not fully reversible (Pauwels et al., 2001). The airflow limitation is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences. The term COPD encompasses chronic obstructive bronchitis, with obstruction of small airways, and emphysema, with enlargement of air spaces and destruction of lung parenchyma, loss of lung elasticity, and closure of small airways. Chronic bronchitis, by contrast, is defined by the presence of a productive cough (due to hypersecretion of mucus) of more than three months’ duration for more than two successive years. There is some epidemiologic evidence that mucus hypersecretion is accompanied by airflow obstruction, perhaps as a result of obstruction of peripheral airways. Most patients with COPD have all three pathologic conditions (chronic obstructive bronchitis, emphysema, and mucus plugging), but the relative extent of emphysema and obstructive bronchitis within individual patients can vary, Vestbo et al., 1996; Bares, 2004a, Barnes, 2004b; Hogg, 2004.
In industrialized countries, cigarette smoking accounts for most cases of COPD, but in developing countries other environmental pollutants (particularly with sulfur dioxide and particulates) and certain occupational chemicals (such as cadmium), are important causes. Passive smoking is also a risk factor.
COPD patients are predisposed to exacerbations, that is, an acute worsening of their respiratory symptoms. An exacerbation of COPD is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management (Rodriguez-Roisin, 2000; Burge and Wedzicha, 2003).
Tracheobronchial infections are believed to be a common cause of exacerbation in COPD, although controversy exists regarding the nature of the infectious agent as well as its exact role (Wedzicha, 2002; White et al., 2003). In addition, exacerbations of COPD are clearly associated with the levels of respirable particles and environmental air pollutants, and these have been linked to hospital admission rates (Rennard and Farmer, 2004). ’
The frequency of exacerbations is linked to disease severity in COPD. Exacerbations, may adversely affect the natural history of these disorders, perhaps by contributing to increased rates of lung function decline, systemic effects, and premature mortality. Unfortunately, to date, there is no widely accepted definition of what constitutes an exacerbation of COPD (Rodriguez-Roisin, 2000). The intensity and duration of increased symptoms required to qualify as an “exacerbation” are difficult to define. Indeed, several definitions co-exist, and many clinical trials employ substantially different criteria or describe poorly the definition(s) used to diagnose exacerbation. The most widely quoted clinical criteria used in the characterization of acute exacerbation of COPD are those described by
Anthonisen et al, (1987). In that study exacerbations were divided into three groups: type 1 exacerbations were characterized by increased breathlessness, increased sputum volume, and new or increased sputum purulence; type 2 included any two of these symptoms; and type 3 consisted of any one of the symptoms together with at least one additional feature, including sore throat or nasal discharge within the last five days; unexplained fever; increased wheeze; increased cough; or a 20% increase in respiratory or heart rate compared with baseline. These criteria have been used as a
-©- benchmark ever since, and all proposed etiologies of exacerbation need to establish their relationship to these key features.
The inhibition of NF-kB is also described as being useful for treating hypoproliferative diseases, e-g., solid tumor and leukemias, on its own or in addition to cytostatic therapy. Inhibition of the NF-xB- activating signal chain at various points or by interfering directly with the transcription of the gene by glucocorticoids, salicylates or gold salts, has been shown as being useful for treating rheumatism.
Patent application WO 01/30774 discloses indole derivatives and US Application Serial No. 10/642,970, discloses indole and benzimidazole derivatives which are able to modulate NF-kB and which exhibit a strong inhibitory effect on IxB kinase. Particularly, US Application Serial No. 10/642,970 discloses indole and benzimidazole derivatives of formula (I), their preparation, [ > Ri
R4 7 -N
AN — R11
R2 MN MN
Now
H _N—H
R3 { pharmaceutical compositions containing these compounds, and methods for the prophylaxis and therapy of a disease associated with an increased activity of IkB kinase comprising administering such compounds. Furthermore, US Application Serial No. 10/642,970 discloses the following compounds of formulae (B), (C), and (D):
-
C]
SN
No
Oy -
N
NH 7 > wa 7s N N . MeO H NH
H,C (B) (compound 43),
C]
NY
~N N
Syn A ==
H JN
NH
. HC (C) (compound 32); and
J
PN
AN N
Eeasa TY
N N
H nn /N
OH /)
N N
H pw /
H sC (D) (compound 48).
However, US Application Serial No. 10/642,970 does not specifically disclose the compound of
Formula (I) wherein M is N; R1 is hydrogen, R2 is carboxyl (-COOH), R3 is methyl, R4 is pyridin-2- yl, R11 is hydrogen, and X is CH.
In view of the aforesaid, there is a need for an inhibitor of IB kinase that operates through the selective inhibition of IKK, particularly an IKK-2 inhibitor. Also desired would be to have such an inhibitor that exhibits a localized activity as opposed to a systemic activity. Such an inhibitor should have a utility in treating a patient suffering from or subject to IKK-2 mediated pathological (diseases) conditions, e.g., asthma, or chronic obstructive pulmonary disorder (COPD), that could be ameliorated by the targeted administering of then inhibitor.
The present invention is directed to a compound having activity as an inhibitor, preferably a selective inhibitor, of IxB (IKK), particularly IKX-2, and to a composition and methods related thereto.
In particular, the present invention is directed to the substantially pure compound of formula (A): ~
Sn
N 0 N
Oy NS oH" N 4
H NH
H,C (A) ~ or a pharmaceutically acceptable salt, or solvate of said compound.
Furthermore, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (A), and a pharmaceutically acceptable carrier.
Furthermore, the present invention is directed to the use of a compound of formula (A) as an inhibitor of IxB kinase.
FIGURE 1 shows a picture of mouse imaging studies in the NF-xB-Luciferase Reporter Mouse Model wherein animals are treated with the Vehicle/PBS solution (negative control animals) and wherein animals have [L-1B-induced NF-kB activation without any compound present [Vehicle/IL-1P] or with increasing doses (0.3 mpk, 1 mpk, 3 mpk, and 10 mpk) of Compound (A) or Compound (B).
FIGURE 2 shows a graph of mouse imaging studies in the NF-kB-Luciferase Reporter Mouse Model showing bioluminescence levels for animals treated with the Vehicle/PBS solution (negative control animals) and wherein animals have IL-1B-induced NF-kB activation without any compound present [Vehicle/IL-1B] or with increasing doses (0.3 mpk, 1 mpk, 3 mpk, and 10 mpk) of Compound (A) or
Compound (B).
FIGURE 3, on the left, shows a graph of Compound (A) levels after i.t. instillation of 0.3 mg/kg of
Compound (A) in lung and plasma tissue; and on the right, shows a graph of Compound (A) and
Compound (B) levels after i.t. instillation of 0.3 mg/kg of Compound (B) in lung and plasma tissue.
FIGURE 4, on the left, shows a graph of the lung exposure of Compound (A) after administering increasing doses (0.01 mpk, 0.03 mpk, 0.10 mpk, and 0.30 mpk) of Compound (A); and on the right, shows a graph of the plasma exposure of Compound (A) after administering increasing doses (0.01 mpk, 0.03 mpk, 0.10 mpk, and 0.30 mpk) of Compound (A).
FIGURE 5, on the left, shows a graph of the lung exposure of Compounds (A) and (B) after administering increasing doses (0.01 mpk, 0.03 mpk, 0.10 mpk, and 0.30 mpk) of Compound (B); and on the right, shows a graph of the plasma exposure of Compounds (A) and (B) after. administering increasing doses (0.01 mpk, 0.03 mpk, 0.10 mpk, and 0.30 mpk) of Compound (B).
List of Abbreviations
As used above, and throughout the description of the invention, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:
Boc,O di-tert-butyl dicarbonate
DIEA N,N-diisopropylethylamine
DMAP 4-dimethylaminopyridine
DMEF dimethylformamide
DMSO dimethylsulfoxide
ESI-MS electrospray ionization mass spectrometry
FAB-MS fast-atom bombardment mass spectrometry
HATU 0-(7-azabenzotriazol-1-y1)-N,N,N' N’ -tetramethyluronium hexaflurophosphate
HPLC high performance liquid chromatography
PBS phosphate-buffered saline in. intranasally
PO oral 1.p. intraperitoneal it. intra-tracheally
Microcystin-LR liver toxin produced by certain cyanobacteria of the genera Anabaena and Oscillatoria mbr millibar
CT -10- mpk mg/kg
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
DTT dithiothreitol
ATP adenosine triphosphate streptavidin-HRP Streptavidin-Horseradish Peroxidase Conjugate
TMB - tetramethylbenzidine pfu plaque-forming units
MDI metered-dose inhaler
DPI dry powder inhaler
As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings. "Compound of the invention", and equivalent expressions, means the compound of formula (A), as hereinbefore described, which expression includes the pharmaceutically acceptable salt and the solvate, e.g., hydrate. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace the salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and they are not intended to exclude other instances when the context
SO permits. “Treating” or "treatment" means prevention, partial alleviation, or cure of the disease. The compound and compositions of this invention are useful in treating conditions that are characterized by the activation of NF-kB and/or enhanced levels of cytokines and mediators that are regulated by NF-kB including, but not limited to TNFa and IL-1B. Inhibition or suppression of NF-«xB and/or NF-xB- regulated genes such as TNFa may occur locally, for example, within certain tissues of the subject, or more extensively throughout the subject being treated for such a disease. Inhibition or suppression of
NF-xB and/or NF-kB-regulated genes such as TNFa may occur by one or more mechanisms, e.g., by inhibiting or suppressing any step of the pathway(s) such as inhibition of IKK. The term "NF-xB- associated condition" refers to diseases that are characterized by activation of NF-xB in the cytoplasm (e.g., upon phosphorylation of IkB). The term "TNFa-associated condition" is a condition characterized by enhanced levels of TNFa. In the instant specification, the term NF-kB-associated condition will include a TNFa-associated condition but is not limited thereto as NF-xB is involved in the activity and upregulation of other pro-inflammatory proteins and genes. The term "inflammatory or immune diseases or disorders” is used herein to encompass both NF-xB-associated conditions and
TNFa-associated conditions, e.g., any condition, disease, or disorder that is associated with release of
NF-kB and/or enhanced levels of TNFa, including conditions as described herein. “Patient” includes both human and other mammals. “Pharmaceutically effective amount” is meant to describe an amount of a compound, composition, medicament or other active ingredient effective in producing the desired therapeutic effect. “Substantially pure” is meant to refer to the compound where it is substantially free of biological or chemical constituents, e.g. isolated from a biological or chemical composition where biological or chemical components are co-isolated therewith, and wherein the analytical purity for the compound is preferably at least 70%. More preferred is where the analytical purity is at least 90%; even further preferred is where the analytical purity is at least 95%; also “substantially pure” is meant to refer to the compound where it is substantially free of prodrugs, e.g., Compound (B).
The invention also relates to a process for preparing the compound of the formula (A), as shown in the following Scheme.
OH OH BOC,0
BOC,0 Sk 1 OMAP SA Len
H—CI H °~ 0” TN °~ ' A 0 aN 0 H ® ° ° °
A 2 > ©. = 4) oO, A Le EL SLA on ow Ao 0 Ao °
A 3 AN 3
HO Vy {( pl
RE LO)
N= H 8 NH -N deprotection 4) = / H 9 —_— _— o = © o ov Yu N N
HN > ~° N I 0 H oH 9 : 10 /
J pry
NaOH / Methanol No r———— H
[0] c—
N N
NH
A /
Starting compounds for the chemical reactions are known or they can be readily prepared using methods known from the literature. US Application Serial No. 10/642,970 describes the preparation of the indole carboxylic acid intermediate (compound 8) used in the coupling step (vi) above. The compounds of the formulae (B), (C) and (D) are prepared as described in US Application Serial No. 10/642,970, which is incorporated herein by reference.
Coupling methods of peptide chemistry that are well known to one skilled in the art (see, e.g., Houben-
Weyl, Methoden der Organischen Chemie {Methods of Organic Chemistry], volumes 15/1 and 15/2,
Georg Thieme Verlag, Stuttgart, 1974, the content of which is incorporated herein by reference), are advantageously used for condensing the compounds. Compounds such as carbonyldiimidazole, carbodiimides such as dicyclohexylcarbodiimide or diisopropylcarbodiimide (DIC), O- ({(cyano (ethoxycarbonyl)methylene)-amino)-N, N, N’, N’-tetramethyluronium tetrafluoroborate (TOTU) or polyphosphoric acid (PPA) are suitable for use as condensing agents or coupling reagents.
The condensations can be carried out under standard conditions. In the condensation, it is necessary for the non-reacting amino groups that are present to be protected with reversible protecting groups.
The same applies to carboxyl groups that are not involved in the reaction, with these groups preferably being present, during the condensation, as (C,-Cg)-alkyl esters, benzyl esters or tert-butyl esters. An amino group protection is not necessary if the amino groups are still present in the form of precursors such as nitro groups or cyano groups and are only formed by hydrogenation after the condensation.
After the condensation, the protecting groups that are present are eliminated in a suitable manner. For example, NO, groups (guanidino protection in amino acids), benzyloxycarbony! groups and benzyl groups in benzyl esters can be eliminated by hydrogenation. The protecting groups of the tert-butyl type are eliminated under acidic conditions while the 9-fluorenylmethyloxy-carbonyl radical is removed using secondary amines.
The invention also relates to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of the formula (A) and a pharmaceutically acceptable carrier.
Because of the pharmacological properties of the compound according to the invention, it is suitable for the treatment of all those patients suffering from or subject to conditions that can be ameliorated by the targeted administration of an inhibitor of IxB kinase to a site where the treatment is better effected by localized versus systemic activity, e.g., asthma, or chronic obstructive pulmonary disorder (COPD).
In practice, the compound of the present invention may be administered in pharmaceutically acceptable dosage form to humans and other animals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, colonic, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the preferred route may vary with for example the condition of the recipient..
Intranasal, intratracheal, or inhalational administration, as well as aerosolization, are particular methods of administering the compound according to the invention.
Combination therapies may improve efficacy and decrease the risk of side effects compared with increasing the dose of a single agent. IKK inhibitors can be combined with bronchodilators including but not limited to short-acting B2-agonists; long-acting 82-agonists such as salmeterol and formoterol; anticholinergic agents such as ipratropium bromide and tiotropium bromide. IKK inhibitors can also be combined with methylxanthines such as theophylline. .
Inhibitors of IKK2 can be combined with several anti-inflammatory therapies including but not limited to immunomodulators directed at various stages of the inflammatory cascade and directed to ameliorating inflammatory processes. Such therapies include, but are not limited to: (A) Inhibitors of cellular recruitment and toxic inflammatory mediators including but not limited to phosphodiesterase-4 inhibitors; inhibitors of p38 mitogen-activated protein kinase; biopharmaceuticals such as anti-tumor necrosis factor-alpha, anti-interleukin-8, and anti-monocyte chemoattractant protein-1; inhibitors of adhesion molecules and chemotactic factors; and molecules that interfere with cell survival and clearance/apoptosis; (B) Inhibitors of proteolytic enzymes including but not limited to inhibitors of neutrophil-derived serine proteases such as neutrophil elastase; and inhibitors of matrix metalloproteinases (MMPs) such as MMP-2, MMP-9 and MMP-12; (C) Antioxidants including but not limited to N-acetylcysteine and inhibitors or scavengers of reactive oxygen species; and toxic peptides such as defensins that can directly cause cell injury; (D) Inhibitors of mucus production including but not limited to inhibitors of mucous genes; and also mucus clearing agents such as expectorants, mucolytics, and mucokinetics; and (E) Antibiotic therapy such as with a ketolide, for example Ketek®.
The drug combinations of the present invention can be provided to a cell or cells, or to a human patient, either in separate pharmaceutically acceptable formulations administered simultaneously or sequentially, formulations containing more than one therapeutic agent, or by an assortment of single agent and multiple agent formulations. However administered, these drug combinations form a pharmaceutically effective amount of components.
The treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amounts of each of the pharmaceutically effective amount of compounds used in combination which together exhibit satisfactory pharmaceutical effectiveness are administered, and so that administration of such pharmaceutically effective amount of compounds in combination is continued only so long as is necessary to successfully treat the patient.
A pharmaceutical composition according to the invention is preferably produced and administered in dosage units, with each unit containing, as the active constituent, a particular dose of the compound.
Pharmaceutically acceptable salts of the compound of formula (A) are within the scope of this invention. The term "salt(s)” means acid or base addition salts formed with acids and bases. In addition, the term "salt(s)” include zwitterion salts (inner salts), i.e., as the compound of formula (A)
contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts may be useful, e.g., in isolation or purification steps that may be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula (A) may be formed, for example, by reacting a compound of the formula (A) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Acid addition salts are formed with the compound of the invention bearing basic moiety(ies) such as an imino nitrogen, amino or mono or disubstituted group is present. Particular acid addition salts are the pharmaceutically acceptable acid addition salts, i.e., salts whose anion is non-toxic to a patient at a pharmaceutical dose of the salt, and so that the beneficial effects inherent in the free form of the compound are not vitiated by side effects ascribable to the anion. The salts chosen are chosen optimally to be compatible with the customary pharmaceutical vehicles and adapted for the form of applicable administration. Acid addition salts of the compound of this invention can be prepared by reaction of the free form of the molecule bearing the basic moiety with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compound of this invention can be prepared either by dissolving the free form of the molecule bearing the base moiety in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free form of the molecule bearing the base moiety and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution. Some suitable acids for use in the preparation of such salts are hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, various organic carboxylic and sulfonic acids, such as acetic acid, citric acid, propionic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methanesulfonic acid, toluenesulfonic acid, mandelic acid, ascorbic acid, malic acid, fatty acids, adipate alginate, ascorbate, aspartate, benzenesulfonate, benzoate, cyclopentanepropionate, digluconate, dodecylsulfate, bisulfate, butyrate, lactate, laurate, lauryl sulfate, maleate, hydroiodide, 2-hydroxy-ethanesulfonate, glycerophosphate, picrate, pivalate, palmoate, pectinate, persulfate, 3-phenyipropionate, thiocyanate, 2- naphthalenesulfonate, undecanoate, nicotinate, hemisulfate, heptanoate, hexanoate, camphorate, camphorsulfonate, and others.
The acid addition salts of the compound of this invention can also be used to regenerate the parent compound of the invention from the salts by the application or adaptation of known methods. For example, the parent compound of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g., aqueous sodium bicarbonate solution or aqueous ammonia solution.
Base addition salts are formed with the compound of the invention bearing the carboxy moiety.
Particular base addition salts are the pharmaceutically acceptable base addition salts, i.e., salts whose cation is non-toxic to a patient at a pharmaceutical dose of the salt, so that the beneficial effects inherent in the free form of the compound are not vitiated by side effects ascribable to the anion. The salts chosen are chosen optimally to be compatible with the customary pharmaceutical vehicles and adapted for the form of applicable administration. Base addition salts of the compound of this invention can be prepared by reaction of the free form of the molecule bearing the acid ‘moiety with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compound of this invention can be prepared either by dissolving the free form of the molecule bearing the acid moiety in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free form of the molecule bearing the acid moiety and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution. Some suitable bases for use in the preparation of such salts are those derived from alkali and alkaline earth metal salts or amines such as: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N -methyl- glucamine, lysine, arginine, omithine, choline. N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)- aminomethane, tetramethylammonium hydroxide, and the like.
The base addition salts of the compound of this invention can also be used to regenerate the parent compound of the invention from the salts by the application or adaptation of known methods. For example, the parent compound of the invention can be regenerated from their base addition salts by treatment with an acid, e.g., hydrochloric acid.
In practice, the compound of the present invention is administered in a suitable formulation to patients such that its activity is particularly localized. It will be appreciated that the preferred route can be varied depending on the site of the condition for which administration is directed.
Pharmaceutically acceptable dosage forms refers to dosage forms of the compound of the invention, and includes, for example, powders, suspensions, sprays, inhalants, tablets, emulsions, and solutions, particularly suitable for inhalation. Techniques and formulations generally may be found in
Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.
If desired, and for more effective distribution, the compound can be microencapsulated in, or attached to, a slow release or targeted delivery systems such as biocompatible, biodegradable polymer matrices (e.g., poly(d,}-lactide co-glycolide)), liposomes, and microspheres and subcutaneously or intramuscularly injected by a technique called subcutaneous or intramuscular depot to provide
S continuous slow release of the compound(s) for a period of 2 weeks or longer.
The compound may also be sterilized, for example, by filtration through a bacteria retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile medium immediately before use.
Formulations suitable for nasal or tracheal administration means formulations that are in a form suitable to be administered nasally or by inhalation to a patient. The formulation may contain a carrier, in a powder form, having a particle size for example in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.). Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. MDI and DPI are feasible means for effecting inhalation therapy by administering a dosage form of the compound of the present invention.
Actual dosage levels of active ingredient(s) in the compositions of the invention may be varied so as to obtain an amount of active ingredient(s) that is (are) effective to obtain a desired therapeutic response for a particular composition and method of administration for a patient. A selected dosage level for any particular patient therefore depends upon a variety of factors including the desired therapeutic effect, on the route of administration, on the desired duration of treatment, the etiology and severity of the disease, the patient's condition, weight, sex, diet and age, the type and potency of each active ingredient, rates of absorption, metabolism and/or excretion and other factors.
Total daily dose of the compounds of this invention administered to a patient in single or divided doses to about 1000 mg, more particularly from about 50 mg to 300 mg, and, further particularly from about 10 mg to 100 mg. However, higher or lower daily doses can also be appropriate. The daily dose can be administered either by means of a once-only administration in the form of a single dosage unit, or of several smaller dosage units, or by means of the multiple administration of subdivided doses at predetermined intervals. The percentage of active ingredient in a composition may be varied, though it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms can be administered at about the same time. A dosage may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. It goes without saying that, for other patients, it will be necessary to prescribe not more than one or two doses per day.
The formulations can be prepared in unit dosage form by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier that constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
Experimental
Mass-spectroscopic methods (FAB-MS, ESI-MS) are used for analyzing. Temperatures are given in degrees Celsius; RT denotes room temperature (from 22°C to 26°C). Abbreviations used are either explained or correspond to customary conventions to one skilled in the art.
The invention is exemplified through the following Examples.
PREPARATION 1
Synthesis of Methyl (3-(N-phenyl-N-2-pyridyl)amino)-2-(di-terr-butoxycarbonylamino)propionate (Scheme 1, Compound 3)
Scheme 1
OH o
Boc,O co L J SW WP PN
N © OMAP oN © A 0] 0] 3 i, x an C ~
CI N 1 enantiomer separation N \ /
CsCO;,, CH,CN >, BUN SL
Ao o A 0 x 3 ) x 3R
Methyl 2-(di-terz-butaxycarbonylamine)acrylate (Scheme 1, Compound 2)
50 g (0.228 mol) of (zert-butoxycarbonyl)serine (1) were dissolved in 300 mL of acetonitrile. 107 g (0.493 mo!) of di-tert-butyl dicarbonate and 2.64 g (22 mmol) of 4-(dimethylamino)pyridine (DMAP) were added. The mixture was stirred at room temperature overnight, after which the solvent was removed under reduced pressure and the residue was taken up in 500 mL of ethyl acetate. The organic
S phase was washed with 500 mL of 1 N BC}, dried using magnesium sulfate and the organic solvents were removed under reduced pressure. 23 g of acrylate 2 were obtained by crystallizing the residue from 200 mL of heptane at -30°C and then filtering with suction. The mother liquor was concentrated and the residue was dissolved in 140 mL of acetonitrile. 31 g (0.142 mol) of di-terz-buty} dicarbonate and 1.26 g (10 mmol) of DMAP were added. After the mixture had been heated at 50°C for 8 h, the solvent was removed in vacuo and the residue was taken up in 500 mL of ethyl acetate. The organic phase was washed with 400 mL of 1 N HCI and dried over magnesium sulfate. After the solvent had been removed in vacuo, a further 31.5 g of the acrylate 2 were obtained by crystallizing from heptane.
Yield: 54.5 g (0.181 mol) 79%. Empirical formula C,4H23NOg; MW. = 301.34; MS (2M*)+Na+) 625.7. '"H NMR (DMSO-ds) 1.40 (s, 18 H), 3.74 (s, 3 H), 5.85 (s, 1 H), 6.28 (s, 1 H).
Methyl (3-(N-phenyl-N-2-pyridyl)amino)-2-(di-tert-butoxycarbonylamino)-propionate (Scheme 1,
Compound 3) 4.96 g (16.5 mmol) of acrylate 2 were mixed with 5.6 g (33 mmol) of 2-anilinopyridine and 32.16 g (98.7 mmol) of cesium carbonate. 50 mL of acetonitrile were added and the mixture was stirred at 45°C for 2 days. The solid was filtered off with suction through kieselguhr and washed 3 times with 100 mL portions of acetonitrile. The combined organic phases were evaporated and the residue was chromatographed on silica gel using 1:1 heptane/diethyl ether. 5.66 g (73%) of the ester 3 were obtained. Empirical formula CpsH3;N306; M.W. = 471.56; MS (M+H) 472.2.
Separation of the enantiomers (Scheme 1, Compound 3(S) and Compound 3(R))
Racemic amino ester 3 was prepared from the corresponding acrylic ester 2 and then resolved into enantiomers 3(S) and 3(R) by means of preparative HPLC using chiral stationary phases such as
Chiralpak AD (Daicel) 100 x 380, RT, flow rate 300 mL/min. The purity of the enantiomers were determined by analytical HPLC such as Chiralpak-AD-H (Daicel) 4.6 x 250, 30°C, flow rate | ml/min, room temperature.
PREPARATION 2
Synthesis of 2-(2-Methylaminopyrimidin-4-yl)-1H-indole-5-carboxylic acid (8) (Scheme 2, Compound 8)
Scheme 2
Roni ~ ~ ~ NaOEVEOH, O°
Fy RED SPRL A CN ssn s 4 © 5 OC “ce 7
H 7 barmie acc, a 1-Dimethylamino-4,4-dimethoxypent-1-en-3-one (Scheme 2, Compound 6) 100 g (0.76 mol) of 3,3-dimethoxy-2-butanone (4) were stirred together with 90.2 g (0.76 mol) of N,N- dimethylformamide dimethyl acetal (5) at 120°C for 48 h. The methanol formed in the reaction was removed continuously from the reaction solution by means of distillation. Crystallization occurred spontaneously when the solution was cooled, with the crystallization being brought to completion By addition of a small amount of heptane. This resulted in 128.24 g of crude product 6 (yield 90%), which was reacted without any further purification. Empirical formula CoH,;NO;; M.W. = 187.24; MS (M+H) 188.2. '"H NMR (DMSO-dg) 1.22 (s, 3 H), 2.80 (s, 3 H), 3.10 (s, 9 H), 5.39 (d, J = 15 Hz, 1 H), 7.59 (d, J =15 Hz, 1 H). [4-(1,1-Dimethoxyethyl)pyrimidin-2-ylJmethylamine (Scheme 2, Compound 7) 1.22 g (53 mmol) of sodium was dissolved in 100 mL of absolute ethanol. 5.8 g (53 mmol) of methylguanidine hydrochloride and 10 g (53 mmol) of 1-dimethylamino-4,4-dimethoxypent-1-en-3- one (6) were added to this solution, while stirring, and the whole was heated at reflux for 4 h. To terminate the reaction, the ethanol was evaporated. The resulting product 7 was used for the subsequent reaction without any further purification. Yield: 11.5 g (58 mmol, quantitative); Empirical formula CoH,sN305; MW. = 197.24; MS (M+H) 198.2. 'H NMR (DMSO-d¢) 1.45 (s, 3 H), 2.78 (5, 3
HH), 3.10(s, 6 H), 6.75 (d, J =3 Hz, 1 H), 7.0-7.1 (s(b), 1 H), 8.30 (d, J=3 Hz, 1 H). 2-(2-Methylaminopyrimidin-4-yl)-1H-indole-S-carboxylic acid (Scheme 2, Compound 8) 5 g (25 mmol) of [4-(1,1-dimethoxyethyl)pyrimidin-2-ylJmethylamine (7) and 3.85 g of 4-hydrazinobenzoic acid were added, at room temperature and while stirring, to 150 mL of 50% sulfuric acid, and the mixture was heated at 130°C for 4 h. The methanol! that was formed in the reaction was removed continuously from the reaction solution by means of distillation. After it had been cooled down to 10°C, the reaction mixture was poured onto 200 mL of ice and adjusted to a pH of about 5.5 with concentrated sodium hydroxide solution. The precipitate of sodium sulfate and product mixture formed was filtered off and the filter residue was extracted several times with methanol. The combined methanol extracts were concentrated and the product 8 was purified by means of flash chromatography (CH,Cla/methanol 9:1). Yield: 0.76 g (11%); Empirical formula
CieH13N.Op; MW, = 268.28; MS (M+H) 269.1. 'H NMR (DMSO-ds) 2.95 (s, 3 H), 6.90-7.10 (s(b), 1
H),7.18(d, J = 3 Hz, 1 H), 7.4 (s, 1 H), 7.58 (d, J = 4.5 Hz, 1 H), 7.80 (d,J=4.5Hz, 1 H),830(,1
H), 8.38 (d, J'= 3 Hz, 1 H), 11.85 (5, 1 H), 12.40-12.60 (s(b), 1 H).
EXAMPLE 1
Synthesis of 2-{ [242-Methylamino-pyrimidin-4-yl)-1H-indole-5-carbony!]-amino}-3-(phenyl-pyridin- 2-yl-amino)-propionic acid (A) ’ Scheme 3 aS x
ALO QL
AA Aen HCI HN N wai 8 HATU, DIEA
ALI— "1 — sa 1 .
LL a, J oN Sn N SN “PCD 2q NaOH, MeOH LCD ! Pi hay 10 . /" 8 " M 2-{[2-(2-Methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl}-amino}-3-(phenyl-pyridin-2-yl- amino)-propionic acid, methyl ester (Scheme 3, Compound 10) 2.9 g of the S enantiomer of 3 (3 (S)) were dissolved in 30 mL of dioxane and the solution was cooled down to 0°C. 30 mL of 4 N HCl in dioxane were added, after which the mixture was allowed to come to room temperature and was then stirred for 12 h. The solvent was removed in vacuo. The residue was taken up in 30 mL of DMF (solution A). 2.47 g (9.2 mmol) of the acid 8 were dissolved in 50 mL of
DMF and cooled down to 0°C. 4.21 g of HATU and 6.4 mL of DIEA were added. After the mixture had been stirred at 0°C for 45 minutes, it was allowed to come to RT and solution A was added. The mixture was stirred at RT for 12 h. The solvent was removed in vacuo and the residue was partitioned between 300 mL of a saturated solution of NaHCO; and 300 mL of ethyl acetate. The aqueous phase was extracted 3 times with 100 mL portions of ethyl acetate and the combined organic phases were washed with 400 mL of a saturated solution of NaCl. The organic phase was dried with magnesium sulfate. The solvents were removed under reduced pressure and the residue was chromatographed on silica gel using 1:3 heptane/ethyl acetate. 1.78 g (55%) of the ester 10 was obtained. Empirical formula CyoHx N05; MW. = 521.58; MS (M+H) 522.2.
2+ [2-(2-Methylamino-pyrimidin-4-yl)-1H-indole-5-carbonyl}-amino}-3-(phenyl-pyridin-2-yl- amino)-propionic acid (Scheme 3, Compound A) 2.0 g (3.8 mmol) of the methyl ester 10 were dissolved in 200 mL of methanol. 1 mL of 2 N aqueous
NaOH was added and the mixture was stirred at room temperature for 12 h. After the solvents had been evaporated, the residue was dissolved in water and the pH was adjusted to ~5 using a saturated solution of NaH,PO,. The resulting precipitate was filtered off and washed with water. After drying under reduced pressure of about 1 mbar at 40°C, 1.95 g (quantitative yield) of the acid A was isolated.
Empirical formula CpHysN,03; MW. = 507.56; MS (M+H) 508.3. '"H NMR (DMSO-d) 2.95 (s, 3 H), 4.22-4.50 (m, 2 H), 4.65-4.72 (m, 1 H), 6.29 — 6.36 (d, 1 H), 6.70 - 6.79 (m, 1 H), 6.90-7.10(sb, 1
H),7.13-7.19 (m, 1 H), 7.22-7.38 (m, 5 H), 7.40-7.48 (m, 3 H), 7.50-7.55 (m, 1 H), 7.57-7.60 (m, 1 H), 7.96 (bs, 1 H), 8.34 — 8.40(m, 2 H), 8.80 — 8.90 (d, 1 H), 11.80 (s, 1 H).
IN VITRO TEST PROCEDURE
IKK-Enzyme ELISA
The assay buffer has the following composition (50 mM HEPES, 10 mM MgCI2, 10 mM B-
Glycerophosphate, 2 pM Microcystin-LR, 0,01% NP-40, 5 mM DTT).
The IKK enzyme preparation was diluted 1:50 (in-house-made preparation) plus test compound in
DMSO (final concentration in well: 2 %).
The assay procedures were as follows: )
Incubation of enzyme and compound for 30 min;
Addition of ImM ATP or 50 uM ATP; pSer36-1kB Peptide (Substrate): 40 uM;
Incubation for 45 min and Addition of anti- pSer32-pSer36-IkB Peptid —antibody;
Incubation for 45 min and transfer to protein-G-coated plate;
Incubation for 90 min followed by 3x washing;
Addition of streptavidin-HRP, then incubation 45 min followed by 6x washing;
Addition of TMB and Incubation for 15 min; and
Stop solution and read using photometer.
The results from the in vitro profiling are shown in Table I below.
Table [ imM ATP 50uM ATP
CBs | sea _ N08
Wc sme I 168 |]
Cv se j____-
In the IKK-enzyme ELISA described above, at a 1 mM ATP, the compound of formula (A) exhibits a 705, 4,725 and 47.5 times greater IB kinase ICs than Compounds (B), (C) and (D), respectively. This data demonstrates an unexpectedly significantly superior activity for Compound (A) relative to
Compounds (B), (C) and (D).
IN VIVO TEST PROCEDURES COMPARISON BETWEEN COMPOUNDS A AND B
NF-kB-induced gene expression contributes significantly to the pathogenesis of inflammatory diseases such as asthma and arthritis. IxB kinase (IKK) is the converging point for the activation of NF-xB by a broad spectrum of inflammatory agonists.
IKK is a multisubunit complex that contains two catalytic subunits, IKK-1 (also known as IKK-o) and
IKK-2 (also known as IKK-B), and the regulatory subunit [KK-y. Gene knock out studies have clearly demonstrated that IKX-2 or IKK-B subunits of the IKK complex are required for NF-xB activation by all known pro-inflammatory stimuli including lipopolysaccharide (LPS), and IL-1. Accordingly, IKK-
B-deficient cells are defective in activation of IKK and NF-kB in response to either tumor necrosis factor alpha (TNFa) or interleukin-1p (IL-18).
In house bio-imaging data have also shown that IL-1P-induced NF-kB activity in the lung is inhibited by the administration of a dominant negative form of IKKB (Adv-IKK-2 DN). Thus a selective inhibitor of IKK-B would not only be of great interest as a potential anti-inflammatory agent but also as a valuable tool to understand the mechanisms regulating NF-xB activation by these inflammatory agonists.
A. NF-xB-Luciferase Reporter Mouse Model
Methods employed for mouse imaging studies with Compound (A) and Compound (B).
General Description
Compounds were used as nanomilled suspensions in 0.2% Tween-80 in PBS and were dosed through the intranasal route.
Intranasal drug and inflammatory stimulus administration: Mice are anesthetized in 4% isoflurane gas in oxygen. A volume of 25 ul is applied to each nostril and the mice are allowed to breathe in the suspension.
Balb/c female mice at 6-8 weeks of age were used for studies in which AdV-NFxB-luciferase reporter was instilled in the lung. To image mice, they are anesthetized with 4% isoflurane in oxygen. Luciferin is delivered 1.p. at a dose of 150 mg/kg. 10 minutes after luciferin injection, the animals are imaged in an IVIS200 system (Xenogen) with a one-minute bioluminescent exposure. Alternatively, 10-15 minutes post luciferin administration, mice are rapidly euthanized and internal tissues are dissected and imaged ex vivo.
B. Dose Response Determination 1-2 x 10° pfu adenovirus-NFxB-luciferase is delivered intranasally 3-5 days prior to stimulation (i.n.) with an inflammatory stimulus (IL-1 or LPS). Animals are dosed i.n. with 0.3-10 mg/kg of compound 30 min- 1 h prior to challenge with 0.5 ug LPS or 50 ng IL-1B. Animals are then imaged once or several times from 1h to 24 h after the inflammatory stimulus is administered.
The results from the in vivo procedures are as follows.
The effects of Compound (A) and Compound (B) on IL-1B-induced NF-kB activation are shown in
Figures 1 and 2. While both compound inhibited in a dose-dependent manner NF-xB activity,
Compound (A) showed superior efficacy with an estimated EDso around 1mg/kg.
C. Pharmacokinetic Procedures
Male Hartley guinea pigs (450-550 g) previously sensitized with ovalbumin were used for the determination of compound levels in lung and plasma. Nanomilled suspensions of Compound (A) and
Compound (B) were dosed via intra-tracheal instillation at 0.01, 0.03, 0.1 and 0.3mg/kg. One hour after dosing, animals were euthanized (Euthasol), and 1 mL blood samples were obtained by cardiac puncture and collected into heparin-coated syringes. Plasma was separated from the cellular component of the blood by centrifugation, and stored at -80°C until assayed. Lungs were dissected out,
blotted dry, weighted and stored in 20-25 mL glass vials individually at -80°C until assayed for compound levels.
Key differences between Compound (A) and Compound (B) pharmacokinetic profiles are illustrated in
Figure 3 using the finding from the highest dose group (0.3 mg/kg). : Figure 3 shows that lung exposure to either Compound (A) or Compound (B) after i.t. instillation of
Compound (B) is low relative to Compound (A) after i.t. administration, suggesting that Compound (B) is rapidly absorbed from the lung.
Figures 3 to 5 also show that Compound (B) would be a weaker candidate for inhalation because 1) It is highly systemically distributed upon exposure, when administered intratracheally; 2) Compound (B) is a prodrug of Compound (A) having a different exposure profile; and 3) Compound (B) produces reduced exposure to Compound (A) in the lung than is obtained by dosing directly with Compound (A).
Compound (A) is a stronger inhalation candidate than Compound (B) because 1) Compound (A) has low systemic exposure after i.t. and PO administration; and 2) Compound (A) should have longer lung residency time.
In addition, support is found that Compound (B) is highly systemically available when administered orally.
The lung to plasma ratio for Compound (A) ranges from 143 to 284 (depending on the dose) whereas the lung to plasma ratio for Compound (B) ranges from 13 to 44 (depending on the dose). These ratios were obtained by dividing the lung compound levels to that of the corresponding plasma levels at the same dose.
Claims (1)
- We Claim:1. A substantially pure compound of formula (A) 9 Nog N N NX H NH / H,C (A) or a pharmaceutically acceptable salt or solvate thereof.2. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula (A) and a pharmaceutically acceptable carrier.3. A compound according to Claim 1 for use in treating a patient suffering from, or subject to, a pathological condition that can be ameliorated by inhibiting IKK-2, wherein a pharmaceutically effective amount of the compound is administered to the patient.4. The compound according to Claim 3 wherein the administering is carried out to result in localized activity.5. The compound according to Claim 3 wherein the pathological condition is asthma, rhinitis, chronic obstructive pulmonary disorder or chronic obstructive pulmonary disorder exacerbations.6. The compound according to Claim 3 wherein the administering is intratracheal, intranasal, inhalational, or by aerosolization administration.17. Use of a compound of Claim | in the manufacture of a medicament for treating a patient suffering from asthma.8. Use of a compound of Claim | in the manufacture of a medicament for treating a patient suffering rhinitis. AMENDED SHEET9. Use of a compound of Claim I in the manufacture of a medicament for treating a patient suffering from chronic obstructive pulmonary disorder.10. Use of a compound of Claim | in the manufacture of a medicament for treating a patient suffering from chronic obstructive pulmonary exacerbations disorder.11. The pharmaceutical composition according to Claim 2 further comprising a pharmaceutically effective amount of a compound selected from the group consisting of a bronchodilator, a long-acting beta-2 agonist, an anticholinergic agents, a methylxanthine and an anti-inflammatory therapy, in admixture with a pharmaceutically acceptable carrier.12. The pharmaceutical composition according to Claim 11, wherein the bronchodilator is a short- acting beta 2-agonist; the long-acting beta 2-agonist is selected from salmeterol and formoterol; the anticholinergic agent is selected from ipratropium bromide and tiotropium bromide; the methylxanthine is theophylline; and the anti-inflammatory therapy is selected from inhibitors of cellular recutiment and toxic inflammatory mediators, inhibitors of proteolytic enzymes, antioxidants, inhibitors of mucus production and antibiotic therapy.13. A compound according to Claim 3 further comprising administering a pharmaceutically effective amount of a compound selected from the group consisting of a bronchodilator, a long-acting beta-2 agonist, an anticholinergic agents, a methylxanthine and an anti-inflammatory therapy, in admixture with a pharmaceutically acceptable carrier.14. A compound according to Claim 13 wherein the bronchodilator is a short-acting beta 2- agonist; the long-acting beta 2-agonist is selected from salmeterol and formoterol; the anticholinergic agent is selected from ipratropium bromide and tiotropium bromide; the methylxanthine is theophylline; and the anti-inflammatory therapy is selected from inhibitors of cellular recutiment and toxic inflammatory mediators, inhibitors of proteolytic enzymes, antioxidants, inhibitors of mucus production and antibiotic therapy.15. A compound according to Claim | or 3, substantially as herein described and exemplified and/or described with reference to the accompany figures.16. A pharmaceutical composition according to Claim 2, substantially as herein described and exemplified and/or described with reference to the accompany figures. AMCNOEC SHEET-27A-17. Use according to any one of Claims 7, 8, 9 or 10 substantially as herein described and exemplified and/or described with reference to the accompany figures. AMCNOED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57014604P | 2004-05-12 | 2004-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200608712B true ZA200608712B (en) | 2008-06-25 |
Family
ID=34969825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200608712A ZA200608712B (en) | 2004-05-12 | 2006-10-18 | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1747215A1 (en) |
JP (1) | JP2007537266A (en) |
KR (1) | KR20070011483A (en) |
CN (1) | CN1950359A (en) |
AR (1) | AR049274A1 (en) |
AU (1) | AU2005245834A1 (en) |
BR (1) | BRPI0511029A (en) |
CA (1) | CA2566213A1 (en) |
EC (1) | ECSP066992A (en) |
GT (1) | GT200500111A (en) |
IL (1) | IL178992A0 (en) |
MA (1) | MA28553B1 (en) |
MX (1) | MXPA06012870A (en) |
NO (1) | NO20065719L (en) |
PA (1) | PA8633101A1 (en) |
PE (1) | PE20060269A1 (en) |
RU (1) | RU2006143758A (en) |
SV (1) | SV2006002111A (en) |
TN (1) | TNSN06338A1 (en) |
TW (1) | TW200605881A (en) |
UY (1) | UY28897A1 (en) |
WO (1) | WO2005113544A1 (en) |
ZA (1) | ZA200608712B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19951360A1 (en) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituted indoles |
DE102004033406A1 (en) * | 2004-07-10 | 2006-02-16 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
US9132087B2 (en) | 2008-04-21 | 2015-09-15 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
AU2010351938B2 (en) | 2010-04-27 | 2014-10-30 | Hutchison Medipharma Limited | Pyrimidinyl indole compounds |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CA3029281A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
CN106588803A (en) * | 2016-11-16 | 2017-04-26 | 西南科技大学 | Novel method for preparing 5-acetylisoxazole |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10237722A1 (en) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indole or benzimidazole derivatives for the modulation of IKappaB kinase |
-
2005
- 2005-05-11 JP JP2007513292A patent/JP2007537266A/en not_active Abandoned
- 2005-05-11 AU AU2005245834A patent/AU2005245834A1/en not_active Abandoned
- 2005-05-11 KR KR1020067023661A patent/KR20070011483A/en not_active Application Discontinuation
- 2005-05-11 BR BRPI0511029-7A patent/BRPI0511029A/en not_active IP Right Cessation
- 2005-05-11 CN CNA200580015046XA patent/CN1950359A/en active Pending
- 2005-05-11 CA CA002566213A patent/CA2566213A1/en not_active Abandoned
- 2005-05-11 GT GT200500111A patent/GT200500111A/en unknown
- 2005-05-11 WO PCT/US2005/016381 patent/WO2005113544A1/en active Application Filing
- 2005-05-11 RU RU2006143758/04A patent/RU2006143758A/en not_active Application Discontinuation
- 2005-05-11 MX MXPA06012870A patent/MXPA06012870A/en not_active Application Discontinuation
- 2005-05-11 PE PE2005000524A patent/PE20060269A1/en not_active Application Discontinuation
- 2005-05-11 EP EP05749733A patent/EP1747215A1/en not_active Withdrawn
- 2005-05-11 AR ARP050101914A patent/AR049274A1/en not_active Application Discontinuation
- 2005-05-12 PA PA20058633101A patent/PA8633101A1/en unknown
- 2005-05-12 UY UY28897A patent/UY28897A1/en unknown
- 2005-05-12 SV SV2005002111A patent/SV2006002111A/en not_active Application Discontinuation
- 2005-05-12 TW TW094115316A patent/TW200605881A/en unknown
-
2006
- 2006-10-18 TN TNP2006000338A patent/TNSN06338A1/en unknown
- 2006-10-18 ZA ZA200608712A patent/ZA200608712B/en unknown
- 2006-10-27 MA MA29415A patent/MA28553B1/en unknown
- 2006-11-01 IL IL178992A patent/IL178992A0/en unknown
- 2006-11-10 EC EC2006006992A patent/ECSP066992A/en unknown
- 2006-12-12 NO NO20065719A patent/NO20065719L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PA8633101A1 (en) | 2006-01-23 |
SV2006002111A (en) | 2006-01-30 |
RU2006143758A (en) | 2008-06-27 |
JP2007537266A (en) | 2007-12-20 |
GT200500111A (en) | 2006-05-09 |
CN1950359A (en) | 2007-04-18 |
BRPI0511029A (en) | 2007-11-27 |
PE20060269A1 (en) | 2006-05-11 |
AU2005245834A1 (en) | 2005-12-01 |
TW200605881A (en) | 2006-02-16 |
CA2566213A1 (en) | 2005-12-11 |
IL178992A0 (en) | 2007-03-08 |
MXPA06012870A (en) | 2007-02-15 |
NO20065719L (en) | 2006-12-12 |
AR049274A1 (en) | 2006-07-12 |
WO2005113544A1 (en) | 2005-12-01 |
KR20070011483A (en) | 2007-01-24 |
TNSN06338A1 (en) | 2008-02-22 |
UY28897A1 (en) | 2005-12-30 |
ECSP066992A (en) | 2006-12-29 |
EP1747215A1 (en) | 2007-01-31 |
MA28553B1 (en) | 2007-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200608712B (en) | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor | |
CA2559036C (en) | 9-substituted 8-oxoadenine compound | |
EP3134410B1 (en) | Inhibiting the transient receptor potential a1 ion channel | |
ES2302033T3 (en) | DERIVATIVES OF QUINOZALINE AS INHIBITORS OF ELASTASA DE LOS NEUROFILOS AND ITS USE. | |
CA2939219A1 (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
CA2826387A1 (en) | Method of inhibiting hamartoma tumor cells | |
RU2661895C2 (en) | Guanidinobenzoic acid ester compound | |
WO2010057877A1 (en) | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors | |
US20070142417A1 (en) | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor | |
JP6441830B2 (en) | Substituted 2-aza-bicyclo [2.2.1] heptane-3-carboxylic acid (cyano-methyl) -amide inhibitors of cathepsin C | |
EP3544965A1 (en) | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase | |
KR20190025545A (en) | Certain protein kinase inhibitors | |
JP2023505587A (en) | Compounds and their use for the treatment of α1-antitrypsin deficiency | |
JP2023505598A (en) | Compounds and their use for the treatment of α1-antitrypsin deficiency | |
JP2023506496A (en) | Compounds and their use for the treatment of α1-antitrypsin deficiency | |
WO2023088418A1 (en) | Compounds as sars-cov-2 inhibitors | |
WO2006076318A1 (en) | Monopotassium salt of an ikb kinase inhibitor | |
WO2019001307A1 (en) | Amide compound, composition containing same, and use thereof | |
US11732007B2 (en) | Therapeutic compounds and methods | |
JP2009539905A (en) | Pyrrolidine derivatives useful for diseases dependent on renin activity | |
US20240139191A1 (en) | Small molecules as larp1 ligands | |
JP2023512281A (en) | Combination therapy for treating MPS1 | |
KR20220117805A (en) | Composition for stimulating interferon genes comprising a benzimidazole derivative as an active ingredient | |
TW202115014A (en) | Compound for treating cystic fibrosis | |
WO2023072966A1 (en) | Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |